Ulcerative Colitis
Ulcerative colitis is a common inflammatory disease of the colon characterized by inflammation and ulceration of the large bowel and rectum. The condition impairs the ability of the large bowel to absorb water which results in diarrhea, the main symptom of the condition.
Ulcerative colitis is a relapsing and remitting condition, meaning symptoms can die down for long periods but then flare-up from time to time. These flare-ups can be sudden and severe. During a period of relapse, symptoms may include bloody diarrhea, abdominal pain and a sudden urge to defecate. Other symptoms include wind, loss of appetite, weight loss, fever and fatigue.
Currently, there is no cure for the condition apart from surgery. However, certain treatments such as corticosteroids or immunosuppressants may be used to ease symptoms by reducing inflammation. Surgery for severe ulcerative colitis that does not respond to treatment involves completely removing the large bowel and re-routing the small bowel so that waste can still be expelled. This procedure is called a colectomy.
In the UK, the incidence of ulcerative colitis is around 1 in 500 and the condition is equally common among males and females. Symptoms can develop at any age, but onset usually occurs between 15 and 30 years of age.
What is Ulcerative Colitis?
Ulcerative colitis is a chronic condition that affects the large intestines, particularly the colon. It is classified as one of the two inflammatory bowel diseases along with Crohn’s disease.
Read More
A new study has provided insights into how microbes protect gut health from the moment of birth.
Scientists at Flinders University have, for the first time, identified a specific type of sensory nerve ending in the gut and how these may 'talk' to the spinal cord, communicating pain or discomfort to the brain.
In a series of four studies published today in Gastroenterology, a journal of the American Gastroenterological Association, Mount Sinai inflammatory bowel disease researchers, describe the identification of predictive tools and a new understanding of environmental factors that trigger IBD.
The U.S. Food and Drug Administration has approved ozanimod, an immune-modulating therapy invented at Scripps Research, for the treatment of adults with relapsing forms of multiple sclerosis.
MIT biological engineers have created a multitissue model that lets them study the relationships between different organs and the immune system, on a specialized microfluidic platform seeded with human cells.
A new study from the University of Birmingham has shown that Fecal Microbiota Transplants (FMT) are highly successful in treating patients with Clostridioides difficile (C.diff) infection.
In a new retrospective study, researchers found that the use of immunosuppressive therapy does not increase the occurrence or recurrence of vulvar or vaginal cancer in women with inflammatory bowel disease (IBD).
Two studies with surprising discoveries: in the elderly, the bacterium E. coli evolves in a way that can become potentially pathogenic and increase the risk of disease and, according to data obtained in another study, the metabolism of the same bacterium present in the microbiota evolves differently if it is alone or accompanied by other bacteria.
Researchers at the University of Texas Southwestern Medical Center and University of Chicago have discovered that bacteria that usually live in the gut can accumulate in tumors and improve the effectiveness of immunotherapy in mice.
Assessments of patients with ulcerative colitis, which is a type of inflammatory bowel disease, are usually conducted via endoscopy and histology. But now, researchers from Japan have developed a system that may be more accurate than existing methods and may reduce the need for these patients to undergo invasive medical procedures.
Ulcerative colitis is a seriously debilitating inflammatory disease of the bowel leading to crippling symptoms that can affect the quality of life severely. Researchers from Stanford University School of Medicine have found in a new study that a missing microbe could be linked to this condition. The study was published today in the latest issue of the journal Cell Host & Microbe.
A team of researchers from University of California, San Diego, have successfully used gut organoids in their lab to show the effects of medications to treat conditions such as “leaky gut”. The study was titled, “The stress polarity signaling (SPS) pathway serves as a marker and a target in the leaky gut barrier: implications in aging and cancer,” and was published in the journal Life Science Alliance today.
Dr. Tim Denning, professor and associate director of the Institute for Biomedical Sciences at Georgia State University, has received a four-year, $1.67 million federal grant to study how an immunological pathway influences inflammatory signaling in the intestine that can lead to chronic human diseases such as inflammatory bowel disease.
Mucus is a protective, slimy secretion produced by goblet cells and which lines organs of the respiratory, digestive, and reproductive systems. Slime production is essential to health, and an imbalance can be life-threatening.
The cells that produce mucus are known to be involved in serious health conditions such as asthma, chronic obstructive pulmonary disease, and even cancer.
Inflammatory bowel disease is a category of refractory inflammatory disease, of which ulcerative colitis and Crohn's disease are the main types.
Investigators at the Case Western Reserve University School of Medicine discovered that blocking interleukin-1α (IL1α), a protein that controls inflammation in the gut, markedly decreases the severity of intestinal inflammation in a mouse model of Crohn's disease (CD).
Inflammatory bowel disease (IBD) is an umbrella term that describes many disorders that involve chronic inflammation of the digestive tract, including ulcerative colitis and Crohn's disease. These conditions are tied to certain alternations in the gut flora.
According to a new study published in the journal Gastroenterology, immune cells of a certain kind which regulate inflammatory processes and even help restore normal gut function after inflammation could be of great use to treat children with inflammatory bowel disease (IBD).
Chronic inflammatory bowel diseases, such as Crohn's Disease and ulcerative colitis, are linked to abnormalities of the gut microbiota in humans and in animals. Patients generally present reduced bacterial diversity in their intestinal flora along with excessive levels of bacteria that express a protein called flagellin, which favors their mobility.